Parkman Healthcare Partners’s PTC Therapeutics PTCT Stock Holding History

Parkman Healthcare Partners’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$35.5M	Buy	435,691 +4,327	+1%	+$312K	3.64%	5
2026 Q1	$29.4M	Buy	431,364 +271,185	+169%	+$19.2M	3.03%	6
2025 Q4	$12.2M	Sell	160,179 -42,184	-21%	-$3.07M	1.16%	30
2025 Q3	$12.4M	Buy	202,363 +20,720	+11%	+$1.08M	1.3%	26
2025 Q2	$8.87M	Sell	181,643 -98,671	-35%	-$4.68M	1.02%	33
2025 Q1	$14.3M	Buy	280,314 +102,946	+58%	+$5.14M	1.69%	25
2024 Q4	$8.01M	Sell	177,368 -17,632	-9%	-$755K	1.07%	36
2024 Q3	$7.23M	Buy	+195,000	New	+$6.53M	0.92%	41

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Parkman Healthcare Partners's PTCT Position: Q2 2026 in Review

Parkman Healthcare Partners increased its PTC Therapeutics (PTCT) stake by 1% in Q2 2026, buying an estimated $312K and bringing the position to 435,691 shares worth $35.5M. The position accounts for 3.64% of the portfolio, ranked #5.

Parkman Healthcare Partners first reported a position in PTCT in Q3 2024 and has held it in 8 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Parkman Healthcare Partners held 435,691 shares of PTC Therapeutics worth $35.5M as of Q2 2026.
Parkman Healthcare Partners bought 4,327 PTC Therapeutics shares in Q2 2026, an estimated $312K.
PTC Therapeutics made up 3.64% of Parkman Healthcare Partners's portfolio in Q2 2026, its #5 holding.
Parkman Healthcare Partners first reported a position in PTC Therapeutics in Q3 2024 and has held it in 8 quarters since.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.